A Comparison of the Checkup Vision Assessment System to Standard Vision Assessment Tools

Launched by DIGISIGHT TECHNOLOGIES, INC. · Aug 15, 2016

Keywords

ClinConnect Summary

BACKGROUND AND INTRODUCTION Neovascular Age - related Macular Degeneration (AMD) is the most common cause of vision loss in subjects over the age of 60. Today in the US over 15 million people live with some form of AMD, and approximately 1.6-1.75 million people have neovascular AMD associated with vision loss. Approximately 200,000 new cases are diagnosed in the US annually; worldwide, approximately 500,000 new cases are diagnosed each year. With the aging of the overall population, prevalence of all forms of AMD is expected to rise to as many as 42 million by 2030, and it is projected that...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female 18 years of age and older
• • Best Corrected Near Visual acuity 20/200 or better in study eye(s)
• • Able and willing to make the required study visits
• • Able and willing to provide consent and comply with study assessments for the full duration of the study.
• • Specific Inclusion Criteria for Subgroup with Normal Eyes
• • Best Corrected Near Visual acuity 20/32 or better in each eye
• • No concurrent systemic illness affecting the retina and vision.
• • Specific Inclusion Criteria for Subgroups with AMD or DR
• • Diagnosis of either AMD or DR (all subgroups qualify)
• Exclusion Criteria:
• • Dementia or other neurologic or psychological limitation that would prevent the patient from performing regular self-testing of visual function
• • Other comorbid ocular pathology affecting vision (with the exception of cataract, pseudophakia, refractive error, and/or presbyopia)
• • Inability to successfully undergo training and certify ability to self-test with Paxos Checkup
• • Inability to return for follow up